Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2012-09-26 Regulatory Filings
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 8-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filing with the SEC, which is used for current reports on significant events. The content describes a press release about the acceptance of a New Drug Application (NDA) by the FDA and related regulatory updates. The document is short (3654 characters) and primarily announces an event rather than providing detailed financial data or a full report. It includes a press release as an exhibit but does not contain financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2012-09-26 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes an announcement about the FDA's advisory committee meeting regarding a new drug application, which is an event disclosure rather than a financial report or detailed management discussion. The document is short (2809 characters) and does not contain financial statements or detailed analysis. It is not an earnings release, annual report, or any other detailed financial filing. It is also not a certification or officer attestation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2012-09-19 English
Major Shareholding Notification 2012
Major Shareholding Notification
2012-09-10 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 4, 2012. It reports Regulation FD Disclosure regarding oral presentations made at a medical congress, with slides attached as exhibits. The content focuses on clinical study results and presentations, not on financial results, management changes, or other report types. The document is short (4343 characters) and primarily serves as a disclosure of presentations rather than a full report or earnings release. It does not contain financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2012-09-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text describes presentations of clinical study data at a medical congress and includes multiple exhibits of study posters. There is no indication that this is a full financial report, audit report, earnings release, or other detailed financial filing. The document is not a report publication announcement since it contains substantive information about the event and exhibits. The nature of the content is an update on clinical study results and other corporate events, which fits the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2012-09-04 English
FORM 4 -
Director's Dealing
2012-08-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.